home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.53 +0.02 (+0.04%)

Official Closing Price Updated: 4:10 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

45 46 Next >

Earnings This Week: AMD, BP And PayPal ↗

October 28, 2022

Find out what to expect from this week's earnings calendar.

Via Talk Markets

10 Health Care Stocks Whale Activity In Today's Session ↗

October 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

GSK Q3 2022 Earnings Conference Call On November 2, 2022 At 08:00 AM ET ↗

October 28, 2022

GSK (NYSE:GSK) will host a conference call at 08:00 AM ET on November 2, 2022, to discuss Q3 2022 earnings results. How to Attend GSK (GSK) Conference Call Follow this link to access the live webcast.

Via Benzinga

GSK Pulls Plug On Late-Stage Asset Under Development For Rheumatoid Arthritis ↗

October 27, 2022

Via Benzinga

GSK One Step Closer To FDA Approval For Anemia Drug For Dialysis Patients ↗

October 27, 2022

Via Benzinga

GSK Walks Away From T-Cell Therapy Pact With Lyell Citing Strategic Actions ↗

October 25, 2022

Via Benzinga

3 Things the Smartest Investors Know About This Beaten-Down Stock ↗

October 20, 2022

Moderna's story may just be beginning.

Via The Motley Fool

FDA Approves GSK's Whooping Cough Vaccine During Pregnancy For Prevention In Infants ↗

October 10, 2022

Via Benzinga

Is Merck Moving Toward Another Blockbuster Drug Launch? ↗

October 26, 2022

Merck will soon share its positive phase 3 clinical trial results for a rare disease drug candidate at an upcoming event.

Via The Motley Fool

GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day ↗

October 25, 2022

Via Benzinga

GSK Plc (NYSE:GSK) Investor Alert: Investigation over Potential Wrongdoing ↗

October 21, 2022

San Diego, CA -- (SBWIRE) -- 10/21/2022 -- An investigation was announced on behalf of investors in NYSE:GSK shares over potential breaches of fiduciary duties by certain officers and directors at GSK...

Via SBWire

Children's Hospitals Strained After Climbing Cases In Respiratory Illnesses In Kids ↗

October 21, 2022

Physicians are reporting a sharp increase in cases of the respiratory syncytial virus (RSV), creating capacity issues in several children's hospitals in the U.S. before the typically busier winter...

Via Benzinga

Peering Into GSK's Recent Short Interest ↗

October 20, 2022

GSK's (NYSE:GSK) short percent of float has risen 12.86% since its last report. The company recently reported that it has 15.83 million shares sold short, which is 0.79% of all regular shares that are...

Via Benzinga

Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny ↗

October 20, 2022

Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to...

Via Benzinga

7 Quality Stocks Selling at a Discount as Q4 Kicks Off ↗

October 19, 2022

Stocks may have just entered a bull market, so bullish investors should look for quality stocks selling at a discount to buy before a rally.

Via InvestorPlace

This Addiction Drug Shows Some Potential Against Long COVID Symptoms ↗

October 19, 2022

Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection.

Via Benzinga

Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm' ↗

October 17, 2022

Via Benzinga

Oil Output Cut May Tip Global Economy Into Recession, Elon Musk's Starship's First Space Tourist, Alphabet Approves Distribution Of Trump's Truth Social App: Top Stories Thursday, Oct. 13 ↗

October 13, 2022

Reuters

Via Benzinga

GSK Touts 'Exceptional Results' From RSV Vaccine Candidate In Older Adults ↗

October 13, 2022

Via Benzinga

Is Pfizer Stock Still Worth Buying After the Pandemic?

October 12, 2022

Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.

Via MarketBeat

Want $1,000 in Passive Income? Don't Make These 3 Mistakes ↗

October 07, 2022

It's easy to get poor returns if you don't diversify your portfolio and carefully calibrate your expectations.

Via The Motley Fool

3 Dirt-Cheap Stocks That Could Soar 48% to 68%, According to Wall Street ↗

October 07, 2022

These stocks could attract both value and growth investors.

Via The Motley Fool

AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial ↗

October 05, 2022

Via Benzinga

DEA-Licensed Pharmaceutical Cannabis Research Company Announces $20M Series A Funding Round ↗

October 04, 2022

The Biopharmaceutical Research Company (BRC), an active DEA pharmaceutical cannabis license holder, announced the completion of a $20 million Series A fundraise, that will enable the company to scale...

Via Benzinga

The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It ↗

October 04, 2022

BARDA will pay Vir up to $1 billion to develop its experimental treatment.

Via Investor's Business Daily

This Is the Best Time to Buy These 7 Long-Term Dividend Stocks ↗

October 03, 2022

Investors want long-term dividend stocks to buy as interest rates rise.

Via InvestorPlace

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

7 Consumer Stocks to Sell Before They Die ↗

September 28, 2022

These are the top consumer stocks to sell before things get worse. These companies are struggling with issues that will take years to fix.

Via InvestorPlace

2 High Yielders Decimated By The Russia-Ukraine War: Is Now The Time To Buy? ↗

September 27, 2022

As the Russia-Ukraine war moves forward, the European economy remains in a fragile state.

Via Benzinga

September 26, 2022

Bloomberg

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com